Ranibizumab Meets Primary Endpoint in Phase 3 Trial for DME

Patients with diabetic macular edema (DME) who received monthly injections of ranibizumab (Lucentis; Genentech, Inc.) were significantly more likely to gain at least 15 letters of BCVA than those who received sham injections, according to the 24-month results of the phase 3 RISE study, which were reported in a company news ...